Clorox Co (NYSE:CLX) Expected to Announce Quarterly Sales of $1.42 Billion

Share on StockTwits

Wall Street analysts expect Clorox Co (NYSE:CLX) to report $1.42 billion in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Clorox’s earnings. The highest sales estimate is $1.44 billion and the lowest is $1.42 billion. Clorox reported sales of $1.47 billion in the same quarter last year, which suggests a negative year over year growth rate of 3.4%. The firm is scheduled to report its next earnings report on Monday, February 3rd.

According to Zacks, analysts expect that Clorox will report full-year sales of $6.17 billion for the current fiscal year, with estimates ranging from $6.15 billion to $6.20 billion. For the next financial year, analysts anticipate that the business will report sales of $6.38 billion, with estimates ranging from $6.28 billion to $6.62 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Clorox.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.05. The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Clorox had a return on equity of 123.56% and a net margin of 13.20%. Clorox’s revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.62 EPS.

A number of brokerages have recently commented on CLX. Wells Fargo & Co reaffirmed a “hold” rating and issued a $150.00 price target on shares of Clorox in a research note on Wednesday, October 2nd. Credit Suisse Group lowered their price target on Clorox from $172.00 to $168.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Bank of America decreased their price objective on Clorox from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, October 3rd. Citigroup decreased their price objective on Clorox from $167.00 to $163.00 and set a “neutral” rating for the company in a research report on Thursday, October 3rd. Finally, Cfra lowered Clorox from a “hold” rating to a “sell” rating in a research report on Friday, November 1st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company. Clorox has a consensus rating of “Hold” and a consensus target price of $152.17.

Shares of CLX stock traded up $0.30 on Tuesday, reaching $152.91. The company had a trading volume of 809,816 shares, compared to its average volume of 807,025. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 4.69. The stock has a market cap of $19.15 billion, a PE ratio of 24.19, a PEG ratio of 4.88 and a beta of 0.39. The company has a 50-day moving average of $150.17 and a 200-day moving average of $153.86. Clorox has a 12 month low of $143.58 and a 12 month high of $166.90.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 29th will be given a $1.06 dividend. The ex-dividend date of this dividend is Tuesday, January 28th. This represents a $4.24 annualized dividend and a dividend yield of 2.77%. Clorox’s dividend payout ratio is presently 67.09%.

In other Clorox news, SVP Denise Garner sold 725 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $146.34, for a total transaction of $106,096.50. Following the completion of the transaction, the senior vice president now owns 5,805 shares of the company’s stock, valued at approximately $849,503.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Andrew J. Mowery sold 5,648 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $146.29, for a total value of $826,245.92. Following the transaction, the senior vice president now directly owns 15,920 shares of the company’s stock, valued at approximately $2,328,936.80. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Strategic Blueprint LLC acquired a new position in Clorox during the 3rd quarter worth approximately $37,000. Transamerica Financial Advisors Inc. acquired a new position in Clorox during the 2nd quarter worth approximately $41,000. Usca Ria LLC acquired a new position in Clorox during the 3rd quarter worth approximately $41,000. Wealthcare Advisory Partners LLC boosted its position in Clorox by 48.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 307 shares of the company’s stock worth $47,000 after acquiring an additional 100 shares during the last quarter. Finally, Mirova acquired a new position in Clorox during the 2nd quarter worth approximately $47,000. 77.64% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.